Off-Label Pacira Warning Letter Dropped From FDA's Website
This article was originally published in The Gray Sheet
Executive Summary
FDA has apparently taken down a warning letter from its website describing off-label marketing violations by Pacira Pharmaceuticals, a drug company that is suing the agency over First Amendment free speech rights. The agency’s response in the lawsuit is due this month.
You may also be interested in...
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.